Reprogramming techniques to generate functional neurons could improve neurodegeneration in the future. A group of researchers from the Institute for Stem Cell Research (ISF) in Germany have found the pathways that play a role in improving the conversion of astrocytes into neurons. Read More

Increased expression of B7-H3 has been previously reported in multiple solid tumors, including pancreatic cancer. In a recent article, researchers from the University of Tuebingen discussed the development of a novel Fc-optimized monoclonal antibody (MAb) targeting B7-H3, named B7-H3-SDIE, as a new immunotherapeutic treatment option for pancreatic cancer. Read More

Amphista Therapeutics Ltd. has announced new datasets with its next-generation bifunctional protein degraders demonstrating in vivo efficacy and the ability to target and degrade proteins in the central nervous system (CNS). Read More

Many patients with cancer in advanced stages develop cachexia, a metabolic disorder characterized by systemic weight loss and muscle and adipose tissue wasting. Read More

The FDA has awarded orphan drug designation to Juvena Therapeutics Inc.’s JUV-161, an... Read More

Psilera Inc. has selected behavioral variant frontotemporal dementia (FTD) as the lead... Read More

Vanda Pharmaceuticals Inc. has announced FDA approval of its IND application to evaluate VCA... Read More

Amyloid Solution Inc. has disclosed microtubule-associated protein tau (PHF-tau; MAPT) and/or... Read More

Harbour Biomed Ltd. has obtained FDA clearance of its IND application to initiate a first-in-human... Read More

To combat trypanosomiasis and leishmaniasis, researchers from the University of Modena and Reggio Emilia and collaborators conducted a study focusing on pteridine reductase 1 (PTR1), a catalytic protein crucial to the folate metabolic pathway in Trypanosomatid parasites. Read More

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have synthesized fibroblast growth factor receptor (FGFR) inhibitors reported to be useful for the treatment of cancer and achondroplasia. Read More

Bayer AG has identified transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer. Read More

One-third of patients with acute myeloid leukemia (AML) present mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. Several first- and next-generation FLT3 inhibitors are currently being used in AML management, but there is a need for new options able to achieve complete and sustained FLT3 signaling suppression. Read More

Relay Therapeutics Inc. has divulged proteolysis targeting chimeric (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an estrogen receptor α (ERα; ESR1)-targeting moiety. Read More

Kissei Pharmaceutical Co. Ltd. has described 3,4-dihydroquinolin-2(1H)-one compounds acting as thyroid-stimulating hormone (thyrotropin) receptor (TSHR) antagonists reported to be useful for the treatment of hyperthyroidism, Graves’ disease and thyroid-associated ophthalmopathy. Read More

Novel nicotinamide phosphoribosyltransferase (NAMPT) positive allosteric modulators (N-PAMs) have been discovered and evaluated by University of Illinois and University of Arizona investigators. Read More

Additional early-stage research and drug discovery news in brief, from: IGC Pharma. Read More